Based on the key indicators related to Oncternal Therapeutics' liquidity, profitability, solvency, and operating efficiency, Oncternal Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Oncternal Therapeutics' Accounts Payable is comparatively stable compared to the past year. Other Current Assets is likely to gain to about 1.6 M in 2024, whereas Cash is likely to drop slightly above 6.4 M in 2024. Key indicators impacting Oncternal Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Oncternal Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Oncternal Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Oncternal Therapeutics.
Net Income
(41.45 Million)
Oncternal
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Depreciation
Other Non Cash Items
Capital Expenditures
Net Income
End Period Cash Flow
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Total Cash From Operating Activities
Total Cash From Financing Activities
Stock Based Compensation
Dividends Paid
Change To Account Receivables
Sale Purchase Of Stock
Investments
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Liabilities
Net Borrowings
Other Cashflows From Investing Activities
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Other Current Liab
Total Current Liabilities
Property Plant And Equipment Net
Accounts Payable
Non Current Assets Total
Common Stock Total Equity
Non Current Liabilities Total
Other Current Assets
Property Plant And Equipment Gross
Common Stock
Non Currrent Assets Other
Inventory
Accumulated Other Comprehensive Income
Short Long Term Debt Total
Current Deferred Revenue
Intangible Assets
Net Receivables
Short Term Debt
Short Term Investments
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Non Current Liabilities Other
Property Plant Equipment
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Tax Expense
Selling General Administrative
Income Before Tax
Total Other Income Expense Net
Total Revenue
Gross Profit
Cost Of Revenue
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Net Interest Income
Interest Income
Probability Of Bankruptcy
Understanding current and past Oncternal Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Oncternal Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Oncternal Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Oncternal Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncternal Therapeutics. Check Oncternal Therapeutics' Beneish M Score to see the likelihood of Oncternal Therapeutics' management manipulating its earnings.
Oncternal Therapeutics Stock Summary
Oncternal Therapeutics competes with CytomX Therapeutics, Assembly Biosciences, Instil Bio, Nuvation Bio, and Protara Therapeutics. Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Oncternal Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Oncternal Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Oncternal Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncternal Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncternal Therapeutics competition to find correlations between indicators driving Oncternal Therapeutics's intrinsic value. More Info.
Oncternal Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Oncternal Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Oncternal Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Oncternal Therapeutics Systematic Risk
Oncternal Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oncternal Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Oncternal Therapeutics correlated with the market. If Beta is less than 0 Oncternal Therapeutics generally moves in the opposite direction as compared to the market. If Oncternal Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oncternal Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oncternal Therapeutics is generally in the same direction as the market. If Beta > 1 Oncternal Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Oncternal Therapeutics Thematic Clasifications
Oncternal Therapeutics is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
Today, most investors in Oncternal Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oncternal Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Oncternal Therapeutics growth as a starting point in their analysis.
Oncternal Therapeutics November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oncternal Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oncternal Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oncternal Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Oncternal Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oncternal Therapeutics's daily price indicators and compare them against related drivers.
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.